GlassScriptPhysician profile
Inna Krasnyansky
NPI 1053312298
$10,593.92
in general payments reported to CMS, 2019-2025
37 companies · $2,282 in 2025
The $2,282 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $627 · 2021: $1,324 · 2022: $2,622 · 2023: $1,669 · 2024: $1,691 · 2025: $2,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,641.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,460.80 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,349.48 | 2021-2025 | Farxiga, Breztri, Lokelma |
| Novo Nordisk INC | $1,127.80 | 2019-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,071.06 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $897.85 | 2020-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $642.42 | 2022-2025 | Kisunla, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $437.28 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $417.39 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $374.97 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $286.61 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $253.86 | 2022-2023 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $252.87 | 2021-2023 | Xarelto |
| Bausch Health US, LLC | $170.35 | 2019-2021 | |
| Astellas Pharma US INC | $168.10 | 2023-2024 | Veozah |
| Axsome Therapeutics, INC. | $142.81 | 2024-2025 | Auvelity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inna Krasnyansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.